Needham & Company
-
Autolus Therapeutics to Participate in Conferences During April 2022
-
Autolus Therapeutics to Participate in Conferences During April 2022
-
Needham & Company Reiterates Autolus Therapeutics plc (AUTL) at Buy, Views Clinical Profile of obe-cel as Potentially Best-in-Class
-
AUTL (AUTL) PT Lowered to $21 at Needham & Company
-
Autolus Therapeutics to Participate in Investor Conferences Through April
-
Autolus Therapeutics to Participate in Investor Conferences Through April
-
Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
-
Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
-
Autolus Therapeutics (AUTL) Prices 14.29M ADS Offering at $7/ADS
-
Autolus Announces Pricing of Public Offering
-
Autolus Announces Pricing of Public Offering
-
Autolus Therapeutics (AUTL) Announces $100 Million Proposed Public Offering in the United States
-
Autolus Announces Proposed Public Offering in the United States
-
Autolus Announces Proposed Public Offering in the United States
-
Companies with NDRs 3/05
-
Needham & Company Starts AUTL (AUTL) at Buy

